Health
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.1 ELAHERE is the first-and-only approved FRα-directed antibody drug
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"The list price will be consistent with the United States to reflect the value of the innovation","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"AbbVie is committed to ensuring that developed nations fully recognize the value of our medicines in improving patient outcomes, consistent with the level of recognition in the United States","length":190,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":285,"olType":false},{"type":"text","content":"NORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced plans to launch ELAHERE® (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.1 ELAHERE is the first-and-only approved FRα-directed antibody drug conjugate (ADC) medicine.","length":582,"tagName":"p"},{"type":"text","content":""Scientific progress in treating ovarian cancer and other serious diseases requires a collaborative approach among all developed nations," said Jeff Stewart, executive vice president and chief commercial officer, AbbVie. "Developed markets must recognize and support the value that innovative therapies bring to patients and societies to help ensure sustainable access and continued investment in medical innovation so that patients everywhere benefit from the next generation of therapies."","length":511,"tagName":"p"},{"type":"text","content":"AbbVie is in discussions with the National Institute for Health and Care Excellence (NICE) to ensure that ELAHERE, which will address a significant unmet need among women suffering from ovarian cancer, is valued fairly. The value given to ELAHERE will determine the ability to launch in the U.K.","length":295,"tagName":"p"},{"type":"text","content":"Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide.2 More than 200,000 women die with the disease globally every year.2 ELAHERE is the first new treatment in 10 years to be licensed for the treatment of women in the U.K. with platinum-resistant ovarian cancer.","len...